1/13
08:01 am
acrs
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
Low
Report
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
1/12
06:55 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Low
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
1/6
06:59 am
acrs
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Low
Report
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
12/30
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
12/19
04:01 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
11/25
08:14 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
01:23 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/7
01:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
06:59 am
acrs
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Low
Report
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/29
07:30 am
acrs
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
10/20
08:08 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.